drugset
Drugs / Nabi-HB
last change Aug 2021 re-read 3 minutes ago

Nabi-HB

also known as Hepatitis B Immune Globulin (Human)

Protein / enzyme biologic

Developed for
chronic hepatitis B virus infection
Investigated by
Biotest Pharmaceuticals Corporation

Trials 1

today NCT00800787 · Ph 3
201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT00800787 Apr → Aug 2010 chronic hepatitis B virus infection Biotest Pharmaceuticals Corporation Withdrawn No outcome recorded

Press releases naming this drug 1 release

DateIssuerRelease
2021-08-09 ADMA Biologics, Inc. ADMA Biologics Announces Commercial Availability of Expanded Vial Size Offerings for BIVIGAM® and NABI-HB® admabiologics.com ↗

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Nabi-HB ClinicalTrials.gov intervention name — accepted as the source's own label NCT00800787 ↗
Known as Hepatitis B Immune Globulin (Human) “Hepatitis b Immune Globulin (Human)(Nabi-HB) 312 IU/L per dose administered subcutaneously.” NCT00800787 ↗
Modality Protein / enzyme biologic “Hepatitis b Immune Globulin (Human)(Nabi-HB)” NCT00800787 ↗
Route Subcutaneous “administered subcutaneously” NCT00800787 ↗